Search Result for Drug name




Atorvastatin is a Hmg-CoA reductase inhibitor. It is primarily indicated in secondary prevention of myocardial infarction and stroke in patients who have symptomatic atherosclerotic disease following acute myocardial infarction or stroke and in primary prevention of arterial disease in patients who are at high risk because of elevated serum cholesterol concentration. (1)

Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina Reduce the risk of hospitalization for CHF Primary and secondary hypercholesterolemia As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C (1,2,3)

Active liver disease or unexplained persistent elevations of serum transaminases. Hypersensitivity to any component of this medication (2)

Myopathy Headache Infrequent elevation of creatinine phosphokinase Rhabdomyolysis Insomnia Dizziness Abdominal pain Constipation, diarrhoea, dyspepsia, flatulence and nausea (2,3)

Increased plasma concentration of atorvastatin and risk of myotoxicity in frequent when used with ketoconazole, itrakonazole, ritonavir and erythromycin Increased risk of rhabdomyolysis when used with fibrates Cyclosporine can increase the bioavailability of atorvastatin (2)

Not used during pregnancy and lactation (2,3)

Available as tablets 5, 10, 20, 40 and 80 mg Dose is 10 mg daily, increased at 4 weeks interval. Max dose 80 mg (1,2)

1. Bersot TP. Drug Therapy for Hypercholesterolemia and Dyslipidemia.  In: Brunton L, Chabner B, Knollmann B eds. Goodman & Gilman’s The Pharmacological basis of Therapeutics. 12th ed. China: McGraw Hill; 2011. P. 877-908. 2. LIPITOR [Internet]. [cited 2013 Oct 6]. Available from: 3. National Formulary of India. 4 th ed. Government of India, Ministry of Health and Family Welfare. India: Indian Pharmacopoeia Commission; 2011